[Serum antibodies in celiac disease]

Area of Science:

• Gastroenterology
• Immunology
• Internal Medicine

Background:

• Celiac disease necessitates lifelong gluten-free dietary adherence to prevent severe complications, including malignancies.
• Understanding evolving clinical classifications (active, silent, latent, potential) and comorbidities is crucial for effective patient management.

Purpose of the Study:

• To review and evaluate the diagnostic utility and efficacy of various autoantibodies in celiac disease.
• To comment on the updated terminology for celiac disease clinical presentations.
• To discuss the association of celiac disease with other medical conditions.

Main Methods:

• Literature review focusing on diagnostic markers and clinical classifications of celiac disease.
• Evaluation of the performance of serum antigliadin antibodies (AGA).
• Assessment of antireticulin (ARA), antiendomysial (EMA), and tissue transglutaminase (tTG) autoantibodies in diagnosis and follow-up.

Main Results:

• The review critically assesses the sensitivity and specificity of AGA, ARA, EMA, and tTG autoantibodies.
• Discussion of the clinical implications of new terminology for celiac disease phenotypes.
• Analysis of the relationship between celiac disease and other associated conditions.

Conclusions:

• Accurate diagnosis and appropriate classification of celiac disease are essential for guiding lifelong gluten-free management.
• Specific autoantibodies, particularly tTG and EMA, play a significant role in the diagnosis and monitoring of celiac disease.
• Continued research into terminology and associated conditions will improve patient outcomes.